Prediction of malignant potential in reflux disease: Are cytokine polymorphisms important?

American Journal of Gastroenterology

Volumn 100, Issue 5, 2005, Pages 1012-1018

  Gough, Martin D ^a   Ackroyd, Roger ^a   Majeed, Ali W ^a   Bird, Nigel C ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; BLOOD SAMPLING; CANCER EPIDEMIOLOGY; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DEMOGRAPHY; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IL 10 GENE; IL 1BETA GENE; IL 1RA GENE; IL 4R GENE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; TNFALPHA GENE; ADENOCARCINOMA; DRUG ANTAGONISM; ESOPHAGUS TUMOR; FORECASTING; GENETICS; IMMUNOLOGY; MIDDLE AGED; REFLUX ESOPHAGITIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; FEMALE; FORECASTING; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKINS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19144366053     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.40904.x     Document Type: Article

References (63)

1. Gallup. Heartburn across America. Gallup organisation national survey. 1986.
2. Kaplan-Machlis B, Spiegler GE, Revicki DA. Health-related quality of life in primary care patients with gastroesophageal reflux disease. Ann Pharmacother 1999; 33(10):1032-36.
3. Neumann CS, Cooper BT. 24 hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus. Gut 1994; 35(10):1352-5.
4. Pass R, Ofman J. Gastroesophageal reflux disease - Should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97(8):1901-9.
5. Romero Y, Cameron AJ, Locke GR, et al. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 1997; 113:1449-56.
6. Inoue S, Matsumoto T, Iida M, et al. Characterisation of cytokine expression in the rectal mucosa of ulcerative colitis: Correlation with disease activity. Am J Gastroenterol 1999; 94(2):2441-6.
7. Giacomelli R, Passacantando A, Parzanese I, et al. Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not Crohn's disease. Clin Exper Immunol 1998; 111(3):532-5.
8. Watanabe M, Ueno Y, Yamazaki M, et al. Mucosal IL-7 mediated immune responses in chronic colitis-IL-7 transgenic mouse model. Immunol Res 1999; 20(3);251-9.
9. Woo P. Cytokine polymorphisms and inflammation. Clin Exper Rheumatol 2000; 18(6):767-71.
10. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: Immunological determinants. Gut 2002; 50(4):451-9.
11. El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: Critical role of H. pylori. Gastroenterology 2000; 118(1):22-30.
12. Diehl SR, Wang Y, Brooks CN, et al. Linkage disequilibrium of interleukin-1 genetic polymorphisms with early onset peridontitis. J Peridontol 1999; 70(4):418-30.
13. Buchs N, Silvestri T, di Giovine FS, et al. IL-4 VNTR gene polymorphism in chronic polyarthritis. The rare allele is associated with protection against destruction. Rheumatology 2000; 39(10):1126-31.
14. Komori A, Yatsunami J, Suganuma M, et al. Tumor necrosis factor as a tumor promotor in BALB/3T3 cell transformation. Cancer Res 1993; 53(9):1982-85.
15. Warzocha K, Salles G, Bienvenu J, et al. Tumor necrosis factor ligand-receptor system can predict outcome in lymphoma patients. J Clin Oncol 1997; 15(2):499-508.
16. Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and downregulates HLA class-I, Class-II and ICAM-1 molecules. Int J Cancer 1997; 71(4):630-7.
17. Nakashima J, Tachibana M, Ueno M, et al. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 1998; 4(7):1743-8.
18. Amati L, Caradonna L, Jirillo E, et al. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications. Ital J Gastroenterol Hepatol 1999; 31(4):313-25.
19. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404(6776):398-402.
20. Fitzgerald RC, Abdall S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett's oesophagus: Implications for disease complications. Gut 2002; 51(3):316-22.
21. Eksteen J, Scott PA, Perry I, et al. Inflammation promotes Barrett's metaplasia and cancer: A unique role for TNF alpha. Eur J Cancer Prev 2001; 10(2):163-6.
22. Wilson AG, di Giovine FS, Duff GW. Genetics of rumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. J Inflamm 1995; 45(1):1-12.
23. di Giovine FS, Cox A, Chaudhary A, et al. Detection and population analysis of IL-1 and TNF gene polymorphisms. In: Balkwill F, ed. Cytokine molecular biology - A practical approach. New edition. Oxford University Press, Oxford, UK. 2000;21-46.
24. Winters C, Jr., Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92(1):118-24.
25. Bremner CG, Bremner RM. Barrett's esophagus. Surg Clin North Am 1997; 77(5):1115-37.
26. Nandurkar S, Talley NJ. Barrett's esophagus: The long and the short of it. Am J Gastroenterol 1999; 94(1):30-40.
27. Cameron AJ, Zinsmeister AR, Ballard DJ, et al. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990; 99(4):918-22.
28. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313(14):857-9.
29. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991; 32(12):1441-6.
30. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American college of gastroenterology. Am J Gastroenterol 1998; 93(7):1028-32.
31. Devesa SS, Blot WJ, Fraumeni Jr., JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83(10):2049-53.
32. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin 1998; 48(1):6-29.
33. van Sandick JW, van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43(2):216-22.
34. Provenzale D, Schmitt C, Wong JB Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94(8):2043-53.
35. Komman KS, Crane A, Wang HY, et al. The interleukin-1 genotype as a severity factor in adult peridontal disease. J Clin Peridontol 1997; 24(1):72-77.
36. Carter MJ, di Giovine FS, Jones S, et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut 2001; 48(4): 461-7.
37. Dinarello CA Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-147.
38. Buchs N, di Giovine FS, Silvestri T, et al. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: Interaction with their plasma levels. Genes Immun 2001; 2(4):222-8.
39. Jeremias J, Ledger WJ, Witkin SS. Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis. Amer J Obstet Gynecol 2000; 182(2):283-5.
40. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 1991; 254:277-9.
41. Heresbach D, Alizadeh M, Dabadie A, et al. Significance of interleukin-1beta and interleukin-1 receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J Gastroenterol 1997; 92(7):1164-9.
42. Stokkers PC, van Aken BE, Basoski N, et al. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut 1998; 43(1):33-9.
43. Carter MJ, di Giovine FS, Cox A, et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 2001; 121(4):805-11.
44. Gore EA, Sanders JJ, Pandley JP, et al. Interleukin-1 beta (+3953) allele 2: Association with disease status in adult peridontitis. J Clin Peridontol 1998; 25(10):781-5.
45. Galbraith GM, Hendley TM, Sanders JJ, et al. Polymorphic cytokine genotypes as markers of disease severity in adult periodontitis. J Clin Periodontol 1999; 26(11): 705-9.
46. Engebretson SP, Lamster IB, Herrera-Abreu M, et al. The influence of interleukin gene polymorphism on expression of interleukin-1beta and tumor necrosis factor-alpha in periodontal tissue and gingival crevicular fluid. J Periodontol 1999; 70(6):567-73.
47. Finkelman FD, Urban JF, Jr. The other side of the coin: The protective role of the TH2 cytokines. J Allergy Clin Immunol 2001; 107(5):772-80.
48. Kondo M, Tamaoki J, Takeyama K, et al. Interleukin-13 induces goblet cell diffrentiation in primary cell culture from guinea pig tracheal epithelium. Am J Respir Cell Mol Biol 2000; 27:536-541.
49. Stacher E, Ullmann R, Halbwedl I, et al. A typical goblet cell hyperplasia in congenital cystic adenomatoid malformation as a possible preneoplasia for pulmonary adenocarcinoma in childhood: A genetic analysis. Human Pathol 2004; 35:565-70.
50. Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995; 109(5):1541-6.
51. Nandurkar S, Talley NJ. Gastroesophageal reflux and adenocarcinoma of the esophagus. N Engl J Med 1999; 341(7):536.
52. Kucharzik T, Lugering N, Winde G, et al. Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10. Clin Exper Immunol 1997; 110(2):296-302.
53. Dummer R, Yue FY, Pavlovic J, et al. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: Suppression by interleukin-10. Brit J Cancer 1998; 77(9):1413-9.
54. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334(26): 1717-25.
55. Jaattela M Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest 1991; 64(6):724-42.
56. Beutler B, Cerami A The biology of cachectin/TNF - a primary mediator of the immune response. Ann Rev Immunol 1989; 7:625-655.
57. Fujiki H, Suganuma M, Komori A, et al. A new tumor promotion pathway and its inhibitors. Cancer Detect Prev 1994; 18(1):1-7.
58. Fujiki H, Suganuma M. Tumor necrosis factor alpha, a new tumor promoter, engendered by biochemical studies of okadaic acid. J Biochem 1994; 115(1):1-5.
59. Suganuma M, Okabe S, Marino MW, et al. Essential role of tumor necrosis alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999; 59(18):4516-8.
60. Huizinga TW, Westendorp RG, Bollen EL, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72(2):149-53.
61. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: Analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001; 30:1415-25.
62. Campos GM, DeMeester SR, Peters JH, et al. Predictive factors of Barrett esophagus: Multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg 2001; 136(11):1267-73.
63. Cameron AJ, Lomboy CT. Barrett's esophagus: Age, prevalence, and extent of columnar epithelium. Gastroenterology 1992; 103(4):1241-5.